Immix Biopharma, Inc.
US ˙ NasdaqCM ˙ US45258H1068

Introduction

This page provides a comprehensive analysis of the known insider trading history of Jason Hsu. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Jason Hsu has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IMMX / Immix Biopharma, Inc. Director 893,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Jason Hsu. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases IMMX / Immix Biopharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IMMX / Immix Biopharma, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2024-12-23 IMMX Hsu Jason 40,000 2.1920 40,000 2.1920 87,680 210 2.9900 31,920 36.41
2024-12-20 IMMX Hsu Jason 7,700 2.1660 7,700 2.1660 16,678
2024-08-22 IMMX Hsu Jason 8,100 2.2510 8,100 2.2510 18,233
2024-08-21 IMMX Hsu Jason 15,000 2.2260 15,000 2.2260 33,390
2024-07-24 IMMX Hsu Jason 6,000 2.1462 6,000 2.1462 12,877
2024-07-18 IMMX Hsu Jason 3,200 2.0748 3,200 2.0748 6,639
2023-12-11 IMMX Hsu Jason 31,000 4.6740 31,000 4.6740 144,894
2023-12-08 IMMX Hsu Jason 25,000 4.8810 25,000 4.8810 122,025
2023-09-15 IMMX Hsu Jason 7,000 2.4852 7,000 2.4852 17,396
2023-09-14 IMMX Hsu Jason 10,000 2.5772 10,000 2.5772 25,772
2023-09-12 IMMX Hsu Jason 30,000 2.8288 30,000 2.8288 84,864
2023-09-11 IMMX Hsu Jason 25,000 2.8912 25,000 2.8912 72,280
2023-09-08 IMMX Hsu Jason 10,000 2.5317 10,000 2.5317 25,317
2021-12-20 IMMX Hsu Jason 50,000 5.0000 50,000 5.0000 250,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMMX / Immix Biopharma, Inc. Insider Trades
Insider Sales IMMX / Immix Biopharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IMMX / Immix Biopharma, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMMX / Immix Biopharma, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Jason Hsu as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2024-12-26 2024-12-23 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 40,000 893,000 4.69 2.19 87,680 1,957,456
2024-12-26 2024-12-20 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 7,700 853,000 0.91 2.17 16,678 1,847,598
2024-08-26 2024-08-22 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 8,100 845,300 0.97 2.25 18,233 1,902,770
2024-08-26 2024-08-21 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 15,000 837,200 1.82 2.23 33,390 1,863,607
2024-07-31 2024-07-24 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 6,000 822,200 0.74 2.15 12,877 1,764,606
2024-07-31 2024-07-18 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 3,200 816,200 0.39 2.07 6,639 1,693,452
2023-12-12 2023-12-11 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 31,000 813,000 3.96 4.67 144,894 3,799,962
2023-12-12 2023-12-08 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 25,000 782,000 3.30 4.88 122,025 3,816,942
2023-09-18 2023-09-15 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 7,000 757,000 0.93 2.49 17,396 1,881,296
2023-09-18 2023-09-14 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 10,000 750,000 1.35 2.58 25,772 1,932,900
2023-09-18 2023-09-12 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 30,000 740,000 4.23 2.83 84,864 2,093,312
2023-09-18 2023-09-11 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 25,000 710,000 3.65 2.89 72,280 2,052,752
2023-09-12 2023-09-08 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 10,000 685,000 1.48 2.53 25,317 1,734,214
2021-12-20 2021-12-20 4 IMMX Immix Biopharma, Inc.
Convertible Note 		C - Conversion 0
2021-12-20 2021-12-20 4 IMMX Immix Biopharma, Inc.
Common Stock 		P - Purchase 50,000 50,000 5.00 250,000 250,000
2021-12-20 2021-12-20 4 IMMX Immix Biopharma, Inc.
Common Stock 		C - Conversion 3,915,913 3,915,913 0.85 3,328,526 3,328,526
2021-12-15 3 IMMX Immix Biopharma, Inc.
Common stock 		675,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)